ARTICLE | Clinical News
HPV-SLP: Phase II started
January 4, 2016 8:00 AM UTC
ISA began an open-label, U.S. Phase II trial to evaluate 100 ug subcutaneous ISA101 every 3-4 weeks for up to 3 doses plus Opdivo nivolumab every 2 weeks starting on day 8 after vaccination with ISA1...